作者: Anders Akerlund , Valerie J Lund , John H Black , László Z Szabó , Camilla Schrewelius
DOI:
关键词:
摘要: This study evaluated the efficacy and tolerability of budesonide in an aqueous nasal spray (BANS) patients with chronic rhinosinusitis. In this double-blind, placebo-controlled, multicentre, parallel-group study, (n = 167) persistent rhinosinusitis symptoms despite 2-weeks' antibiotic treatment were randomised to receive BANS 128 micrograms b.i.d. or placebo for 20 weeks. Morning combined symptom scores (CSS) receiving decreased by a mean -1.85 (95% CI -2.27, -1.43), versus -1.02 (-1.43, -0.61) group (p 0.005); corresponding values evening CSS -1.78 (-2.22, -1.35) (-1.45, -0.60), respectively 0.012). produced significant reductions congestion discharge scores, improved patients' sense smell (morning only), placebo. Peak inspiratory flow (PNIF) increased significantly during treatment. allergic patients, < 0.001) reduced both morning -1.40 (-2.18, -0.62) -1.37 (-2.15, -0.58) from baseline placebo, but changes non-allergic (morning: -0.04 [-0.95, 0.87]; evening: 0.14 [-0.81, 1.09]) not significant. PNIF was 0.01) is effective well-tolerated